Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353285 | 0.85 | CA2 (0.51) | CA2CA1CA9CA12CA14 | |
| SCHEMBL2773556 | 0.85 | CA2 (0.55) | CA2CA1CA9CA12CA14 | |
| SCHEMBL2807317 | 0.85 | APEX1 (0.53) | ALDH1A1HSD17B10PHLPP2POLBKDM4E | |
| SCHEMBL1017780 | 0.83 | LMNA (0.61) | ALDH1A1HSD17B10PHLPP2 | |
| SCHEMBL3496072 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HSD17B10PHLPP2POLBKDM4E | |
| SCHEMBL7824801 | 0.82 | CA2 (0.55) | CA2CA1CA9CA12CA14 | |
| SCHEMBL1279551 | 0.81 | LMNA (0.46) | ALDH1A1HSD17B10PHLPP2POLBKDM4E | |
| SCHEMBL31637076 | 0.81 | RXRB (0.45) | ALDH1A1HSD17B10PHLPP2POLBKDM4E | |
| SCHEMBL27530309 | 0.81 | ALDH1A1 (0.57) | CA2CA1CA9CA12CA14 | |
| SCHEMBL15606239 | 0.80 | MYC (0.53) | CA2CA1CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12467928-B2 | N-terminal modifier agents and binders for treating and analyzing peptides | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| US-20240377408-A1 | N-TERMINAL MODIFIER AGENTS AND BINDERS FOR TREATING AND ANALYZING PEPTIDES | DF PEPTIDE ACQUISITION LLC | 2024-11-14 | — | — | US | disclosed |
| EP-4271997-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3896521-B1 | POLYMER, PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING METHOD, METHOD OF FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC COMPONENT | SHINETSU CHEMICAL CO (JP) | 2022-12-14 | — | — | EP | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022147334-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147334-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11333975-B2 | Polymer, photosensitive resin composition, patterning method, method of forming cured film, interlayer insulating film, surface protective film, and electronic component | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3896521-A1 | POLYMER, PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING METHOD, METHOD OF FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC COMPONENT | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| CN-102574857-A | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors | LEO PHARMA AS | 2012-07-11 | — | — | CN | disclosed |
| EP-2451813-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | Leo Pharma A/S (DK) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | CA2 3427/4885CA1 2128/4885CA9 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.